News

Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously ...
When executed with precision and transparency, ECAs can enhance trial efficiency, expand access and support evidence—while ...
ASCO Annual Meeting abstracts of phase III trials consistently reflect final published results, but some differences were observed that warrant caution in using abstract results to shape treatment ...